Stocktoria
SPRUCE BIOSCIENCES, INC. SPRB
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-10-09
SPRUCE BIOSCIENCES, INC. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $4.9M | $10.1M | $0 | — | — | — |
| R&D expense | $19.5M | $46.4M | $49.4M | $35.2M | $30.7M | $23.9M | $10.8M |
| Operating income | -$36.5M | -$56.2M | -$52.0M | -$47.3M | -$42.1M | -$29.4M | -$13.1M |
| Interest expense | $90,000 | $307,000 | $483,000 | $420,000 | $345,000 | $323,000 | $65,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$39.0M | -$53.0M | -$47.9M | -$46.2M | -$42.3M | -$29.5M | -$13.1M |
| EPS (diluted) | $-50.83 | $-96.40 | $-1.24 | $-1.96 | $-1.81 | — | — |
| Operating cash flow | -$33.3M | $56.0M | $33.3M | $41.7M | $35.9M | -$27.5M | -$12.6M |
| Free cash flow | — | $56.0M | $33.3M | $41.7M | $35.8M | -$27.6M | -$12.6M |
| Cash & equivalents | $48.9M | $38.8M | $96.3M | $24.5M | $42.7M | $157.2M | $3.9M |
| Total assets | $53.0M | $45.2M | $103.9M | $85.6M | $126.5M | $162.9M | $4.7M |
| Total liabilities | $10.5M | $16.4M | $27.4M | $17.2M | $15.1M | $13.5M | $7.5M |
| Shareholders' equity | $42.5M | $28.8M | $76.5M | $68.5M | $111.4M | $149.4M | -$30.6M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | -100.0% | -51.3% | — | — | — | — | — |
| Free cash flow growth | — | +68.2% | -20.1% | +16.4% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.